Patents Represented by Attorney Maria V. Marucci
-
Patent number: 8283344Abstract: The invention is directed to a method of treating severe neutropenia, and in particular, cyclic neutropenia (CN) or severe congenital neutropenia (SCN), in a patient in need of such treatment comprising: administering a therapeutically effective amount of a compound of Formula (I) or a pharmaceutically acceptable salt thereof.Type: GrantFiled: September 5, 2008Date of Patent: October 9, 2012Assignees: Merck & Co., Inc., University of WashingtonInventors: David C. Dale, Paul E. Finke, Richard A. Mumford, Andranik Andrew Aprikyan
-
Patent number: 8158671Abstract: The invention is directed to indole and indoline cyclopropyl amide derivatives as EP4 receptor antagonists useful for the treatment of EP4 mediated diseases or conditions, such as acute and chronic pain, osteoarthritis, rheumatoid arthritis and cancer. Pharmaceutical compositions and methods of use are also included.Type: GrantFiled: February 22, 2008Date of Patent: April 17, 2012Assignee: Merck Canada Inc.Inventors: Michael Boyd, John Colucci, Yongxin Han
-
Patent number: 8124628Abstract: The instant invention provides compounds of Formula II which are 5-lipoxygenase activating protein inhibitors. Compounds of Formula II are useful as anti-atherosclerotic, anti-asthmatic, anti-allergic, anti-inflammatory and cytoprotective agents.Type: GrantFiled: April 6, 2007Date of Patent: February 28, 2012Assignee: Merck Sharp & Dohme Corp.Inventors: Lin Chu, Bing Li, Anthony K. Ogawa, Hyun O. Ok, Debra L. Ondeyka, Minal Patel, Rosemary Sisco, Feroze Ujjainwalla, Jinyou Xu
-
Patent number: 8063102Abstract: The present invention relates to novel tetrahydronaphthalen-2-ol derivatives, to pharmaceutical compositions comprising these compounds and to their use in therapy, in particular to their use for the manufacture of a medicament for the prevention or treatment of lower urinary tract symptoms, benign prostate hyperplasia, prostate cancer, hot flushes, anxiety, depression, breast cancer, medullary thyroid carcinoma, ovarian cancer, inflammatory bowel disease, arthritis, endometriosis, and colon cancer.Type: GrantFiled: March 11, 2010Date of Patent: November 22, 2011Assignee: N.V. OrganonInventors: Herman Thijs Stock, Neeltje Miranda Teerhuis, Gerrit Herman Veeneman
-
Patent number: 8017605Abstract: Compounds described by the chemical formula (I) or pharmaceutically acceptable salts thereof: are inhibitors of p38 and are useful in the treatment of inflammation such as in the treatment of asthma, COPD, ARDS, rheumatoid arthritis, rheumatoid spondylitis, osteoarthritis, gouty arthritis and other arthritic conditions; inflamed joints, eczema, psoriasis or other inflammatory skin conditions such as sunburn; inflammatory eye conditions including conjunctivitis; pyresis, pain and other conditions associated with inflammation.Type: GrantFiled: June 10, 2009Date of Patent: September 13, 2011Assignee: Merck Sharp & Dohme Corp.Inventors: Soumya P. Sahoo, Meng-Hsin Chen, Kevin D. Dykstra, Hiroo Koyama, Peter T. Meinke, Stephen J. O'Keefe, Ginger Xu-qiang Yang
-
Patent number: 8013159Abstract: The invention is directed to quinoline derivatives as prostaglandin E type receptor antagonists useful for the treatment of EP4 mediated diseases or conditions, such as acute and chronic pain, osteoarthritis, rheumatoid arthritis and cancer. The derivatives have the following structure of formula (I): wherein A and B represents either a nitrogen atom or a CH group with the proviso that they cannot both simultaneously be CH, Q can represent a nitrogen or a carbon atom, and Y and Z are either a nitrogen atom, a N(O) group or a C(R5) group. Pharmaceutical compositions comprising the derivatives of formula (I) are also included.Type: GrantFiled: May 15, 2006Date of Patent: September 6, 2011Assignee: Merck Canada Inc.Inventors: Michel Belley, Jason Burch, John Colucci, Julie Farand, Mario Girard, Yongxin Han
-
Patent number: 8003661Abstract: The invention is directed to naphthalene and quinoline sulfonylurea derivatives as EP4 receptor antagonists useful for the treatment of EP4 mediated diseases or conditions, such as acute and chronic pain, osteoarthritis, rheumatoid arthritis and cancer. Pharmaceutical compositions and methods of use are also included.Type: GrantFiled: March 25, 2008Date of Patent: August 23, 2011Assignee: Merck Canada Inc.Inventors: Jason Burch, Julie Farand, Yongxin Han, Claudio Sturino
-
Patent number: 7888394Abstract: Pharmacological inhibition of fatty acid amide hydrolase (FAAH) activity leads to increased levels of fatty acid amides. The alkylcarbamic acid aryl ester of Formula (I), KDS-4103, is a FAAH inhibitor. Described herein is a process for the preparation of the compound of Formula (I), characterization of polymorphs of the FAAH inhibitor, and their uses therof.Type: GrantFiled: August 16, 2007Date of Patent: February 15, 2011Assignee: N.V. OrganonInventors: David Putman, Olivier Dasse
-
Patent number: 7879875Abstract: Compounds described by the chemical formula (I) or pharmaceutically acceptable salts thereof: (I) are inhibitors of p38 and are useful in the treatment of inflammation such as in the treatment of rheumatoid arthritis, rheumatoid spondylitis, osteoarthritis, gouty arthritis and other arthritic conditions; inflamed joints, eczema, psoriasis or other inflammatory skin conditions such as sunburn; inflammatory eye conditions including conjunctivitis; pyresis, pain and other conditions associated with inflammation.Type: GrantFiled: August 8, 2006Date of Patent: February 1, 2011Assignee: Merk Sharp & Dohme Corp.Inventors: Meng-Hsin Chen, James B. Doherty, Robert Tynebor, Swaminathan R. Natarajan, Zhen Li, Soumya P. Sahoo
-
Patent number: 7846966Abstract: The invention provides chroman compounds having formula 1 wherein R1 is (1C-4C)alkyl, (2C-4C)alkenyl or (2C-4C)alkynyl, and independently R1 has a cis-orientation in relation to the exocyclic phenyl group at the 2-position of the skeleton; R4 is H, Hal, CF3, OH or (1C-2C)alkyloxy; R2, R3, and R5 are independently H, Hal, CF3, (1C-4C)alkyl, (2C-4C)alkenyl or (2C-4C)alkynyl and prodrugs thereof for the manufacture of a medicine for estrogen-receptor related treatments.Type: GrantFiled: May 8, 2009Date of Patent: December 7, 2010Assignee: N.V. OrganonInventors: Gerrit Herman Veeneman, Neeltje Miranda Teerhuis
-
Patent number: 7735366Abstract: Disclosed is an improved method for measuring the volume of an animal paw, suitable for use in a rat paw edema assay. Also disclosed is a novel apparatus for measuring the volume of liquid displaced by the insertion of an object into a liquid filled cup (1) which is on a cup holder basin (3), the liquid filled cup and cup holder basin being inside a rectangular support assembly (5), the measurement obtained by determining the buoyant force produced as a result of the displacement of the liquid by the animal paw.Type: GrantFiled: May 6, 2006Date of Patent: June 15, 2010Assignee: Merck Sharp & Dohme Corp.Inventors: Gary S. Kath, Michael K. Wismer, Paul R. Augustine, Cordelia G. Rasa
-
Patent number: 7521207Abstract: The Macaca mulatta (rhesus monkey) Nur77 (rhNur77) nuclear receptor and the nucleic acid encoding the rhNur77 nuclear receptor are described. Further described are methods for identifying analytes that modulate expression or activity of the rhNur77 nuclear receptor. Analytes that affect Nur77 expression or activity may be used to treat or inhibit inflammatory diseases, for example, osteoarthritis and various bone, neurological, and prostrate disorders. The rhNur77 may also be used to treat various cancers, for example, prostate, ovarian, colon, lung, and gastric cancer.Type: GrantFiled: March 16, 2006Date of Patent: April 21, 2009Assignee: Merck & Co., Inc.Inventors: Carlo J. Gambone, Azriel Schmidt